Skip to main content
Premium Trial:

Request an Annual Quote

Bayer, NeoGenomics Launch Free NTRK Fusion Testing Program

NEW YORK – Bayer and NeoGenomics on Tuesday launched Test4TRK, a program offering no-cost NTRK gene fusion testing to patients with RAI-refractory differentiated thyroid cancer and metastatic colorectal cancer with high microsatellite instability.

NTRK fusions are known to drive cancers, and since they tend to occur in RAI-refractory differentiated thyroid cancer and metastatic colorectal cancer with MSI-high status, testing patients for this biomarker may aid in their disease management.

Within the program, Bayer will cover the cost of testing for up to 500 patients in the US, but not the costs of extracting a tumor specimen. Enrolled patients will be tested by NeoGenomics on an RNA-based next-generation sequencing test, called NTRK NGS Fusion Profile. If patients have sufficient tissue, they will also receive the Pan-Tropomyosin Receptor Kinase Immunohistochemistry test.

"The results of a genomic cancer test may be a deciding factor in treatment selection, especially for patients with differentiated thyroid cancer who have limited options," said Marcia Brose, director of the Center for Rare Cancers and Personalized Therapy at the Abramson Cancer Center of the University of Pennsylvania, and a collaborator in developing the testing platform. "If we implement comprehensive genomic testing early upon diagnosis to uncover NTRK gene fusions, we may have a deeper understanding of patients' tumors in aiding treatment decisions."

Brose serves in an advisory capacity for Bayer and receives honoraria and funding for research. In addition to working with Brose, drugmaker Bayer developed the Test4TRK program in collaboration with patient organizations Thyroid Cancer Survivors’ Association and Fight Colorectal Cancer.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.